Seven deals raised a combined $1.2 billion this past week and first day returns averaged 16%. Performance was particularly strong for the healthcare space; Chinese cancer biotech Zai Lab led the pack, returning 55% on its first day,...read more
Seven deals are on the IPO calendar to raise a combined $1.6 billion in the week ahead. Chinese logistics provider Best leads the pack with an $869 million offering (the largest IPO of Q3), followed by leading Latin American...read more
Zai Lab, a Chinese cancer biotech advancing late-stage drugs licensed from large pharmas, announced terms for its IPO on Friday. The Shanghai, China-based company plans to raise $100 million by offering 5.9 million shares at a price range of $16 to $18. At...read more
No US IPOs priced this week. Filing activity remained muted with one Chinese luxury e-commerce company, two micro-cap healthcare deals, and two tech-focused SPACs joining the pipeline, while another mico-cap biotech withdrew. With the...read more
US IPO Weekly Recap: An active week as 7 IPOs average 16% pop
Seven deals raised a combined $1.2 billion this past week and first day returns averaged 16%. Performance was particularly strong for the healthcare space; Chinese cancer biotech Zai Lab led the pack, returning 55% on its first day,...read more
US IPO Week Ahead: Most active week of the quarter with 7 IPOs, led by Alibaba-backed Best
Seven deals are on the IPO calendar to raise a combined $1.6 billion in the week ahead. Chinese logistics provider Best leads the pack with an $869 million offering (the largest IPO of Q3), followed by leading Latin American...read more
Chinese cancer biotech Zai Lab sets terms for $100 million IPO
Zai Lab, a Chinese cancer biotech advancing late-stage drugs licensed from large pharmas, announced terms for its IPO on Friday. The Shanghai, China-based company plans to raise $100 million by offering 5.9 million shares at a price range of $16 to $18. At...read more
US IPO Weekly Recap: 5 new filings while summer slowdown in full effect
No US IPOs priced this week. Filing activity remained muted with one Chinese luxury e-commerce company, two micro-cap healthcare deals, and two tech-focused SPACs joining the pipeline, while another mico-cap biotech withdrew. With the...read more